Roffman Miller Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-6,637
| Closed | -$412K | – | 74 |
|
|
2020
Q4 | $412K | Sell |
6,637
-68
| -1% | -$4.18K | 0.04% | 70 |
|
|
2020
Q3 | $404K | Sell |
6,705
-1,364
| -17% | -$82.1K | 0.04% | 70 |
|
|
2020
Q2 | $474K | Buy |
8,069
+524
| +7% | +$31.3K | 0.05% | 95 |
|
|
2020
Q1 | $421K | Sell |
7,545
-1,422
| -16% | -$86.9K | 0.05% | 72 |
|
|
2019
Q4 | $576K | Sell |
8,967
-189
| -2% | -$10.8K | 0.06% | 71 |
|
|
2019
Q3 | $464K | Sell |
9,156
-43
| -0.5% | -$2.02K | 0.05% | 73 |
|
|
2019
Q2 | $417K | Buy |
9,199
+1,294
| +16% | +$60.3K | 0.04% | 73 |
|
|
2019
Q1 | $378K | Buy |
+7,905
| New | +$394K | 0.04% | 72 |
|
|
2018
Q4 | – | Sell |
-8,007
| Closed | -$497K | – | 72 |
|
|
2018
Q3 | $497K | Buy |
8,007
+211
| +3% | +$12.5K | 0.06% | 68 |
|
|
2018
Q2 | $431K | Sell |
7,796
-119
| -2% | -$6.43K | 0.05% | 57 |
|
|
2018
Q1 | $501K | Buy |
7,915
+12
| +0.2% | +$772 | 0.06% | 57 |
|
|
2017
Q4 | $484K | Sell |
7,903
-141
| -2% | -$8.82K | 0.06% | 58 |
|
|
2017
Q3 | $513K | Sell |
8,044
-601
| -7% | -$35.1K | 0.07% | 58 |
|
|
2017
Q2 | $482K | Sell |
8,645
-3,309
| -28% | -$180K | 0.07% | 58 |
|
|
2017
Q1 | $650K | Buy |
11,954
+2,536
| +27% | +$139K | 0.09% | 55 |
|
|
2016
Q4 | $550K | Sell |
9,418
-395
| -4% | -$21.6K | 0.08% | 56 |
|
|
2016
Q3 | $529K | Sell |
9,813
-196
| -2% | -$12.6K | 0.09% | 53 |
|
|
2016
Q2 | $736K | Sell |
10,009
-94
| -0.9% | -$6.64K | 0.12% | 53 |
|
|
2016
Q1 | $645K | Sell |
10,103
-792
| -7% | -$49.9K | 0.11% | 54 |
|
|
2015
Q4 | $749K | Sell |
10,895
-533
| -5% | -$35.2K | 0.14% | 53 |
|
|
2015
Q3 | $677K | Buy |
11,428
+552
| +5% | +$35K | 0.13% | 54 |
|
|
2015
Q2 | $724K | Sell |
10,876
-280
| -3% | -$18.5K | 0.14% | 54 |
|
|
2015
Q1 | $720K | Buy |
11,156
+111
| +1% | +$6.95K | 0.14% | 55 |
|
|
2014
Q4 | $652K | Sell |
11,045
-852
| -7% | -$48K | 0.13% | 57 |
|
|
2014
Q3 | $609K | Sell |
11,897
-540
| -4% | -$27K | 0.12% | 59 |
|
|
2014
Q2 | $603K | Sell |
12,437
-297
| -2% | -$14.6K | 0.13% | 59 |
|
|
2014
Q1 | $662K | Buy |
12,734
+985
| +8% | +$52.4K | 0.15% | 59 |
|
|
2013
Q4 | $624K | Buy |
11,749
+178
| +2% | +$9.07K | 0.14% | 63 |
|
|
2013
Q3 | $536K | Buy |
11,571
+4
| +0% | +$176 | 0.14% | 64 |
|
|
2013
Q2 | $517K | Buy |
+11,567
| New | +$502K | 0.14% | 65 |
|
Other funds holding BMY
Roffman Miller Associates's BMY Position: Q1 2021 in Review
Roffman Miller Associates sold out of Bristol-Myers Squibb (BMY) in Q1 2021, closing a stake of 6,637 shares — an estimated $412K sold.
Roffman Miller Associates first reported a position in BMY in Q2 2013 and held it in 30 quarters. The position peaked at $749K in Q4 2015. 2,369 funds tracked by Wall St. Rank hold BMY as of Q1 2021.
- Roffman Miller Associates reported no remaining Bristol-Myers Squibb position as of Q1 2021 after selling out during the quarter.
- Roffman Miller Associates sold 6,637 Bristol-Myers Squibb shares in Q1 2021, an estimated $412K.
- Roffman Miller Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 30 quarters.
- Roffman Miller Associates's Bristol-Myers Squibb position peaked at $749K in Q4 2015.
- 2,369 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2021.
Based on Roffman Miller Associates's 13F filing for Q1 2021, filed 16 Apr 2021.